The Jasperate offering is now closed and is no longer accepting investments.


The inventors of the J-needle™

Regulation Crowdfunding
Health Tech
Accepting International Investment
Play video

Reduce Pain and Suffering Caused by Trigger Finger

Invest in Jasperate

Our co-founder, Dr. Stephen Soloway is a renowned Rheumatologist who's double board certified in internal medicine and rheumatology. As a practicing physician, he's been treating trigger finger, arthritis, lupus, gout, osteoporosis, psoriasis, and other pain areas for 30 years.  Some of his many accomplishments include Philadelphia Magazine Top Doctors since 2006 (Doctor with the most consecutive years on the list), Patient's Choice Award, Most Compassionate Doctor, Castle Connolly America's Top Doctors, Presidential Who's Who, and many others too numerous to list. In addition, Dr. Soloway was recently appointed by the Governor of New Jersey to the Board of Medical Examiners and has faculty appointments at the Medical College of Pennsylvania, Drexel University College of Medicine, and Rowan University School of Osteopathic Medicine. He is published in The New England Journal of Medicine, The Journal of Rheumatology, Clinical and Experimental Rheumatology, The Rheumatologist, and others.

"Over the years I've seen and treated hundreds and hundreds of patients that suffer from trigger finger. We've developed this new innovative needle that we call the J-needle™ that can be used to reduce and sometimes completely eliminate the pain and suffering from this debilitating health concern. We're excited that we're now on the path to not only help our trigger finger patients, but also those that have back instrumentation and other ailments."

-Dr. Stephen Soloway

The Opportunity

$1.00/share of Non Voting Common Stock

When you invest you are betting the company’s future value will exceed $510,000 if the Offering Minimum is reached or $600,000 if the Offering Maximum is reached.


Invest $1,000: Conference call with our founders to discuss medicine, entrepreneurship or anything you'd like.

Invest $5,000: Have lunch with our founders at or near our offices.

*All perks occur after the offering is completed.

What We Have Accomplished So Far

We are a startup firm in the truest sense. We're a pre-earning and pre-revenue company. Our principal employees will not take any salaries until revenue is recognized. We incorporated in March 2017. Over the first couple of months, the founders provided the initial funding, developed the technology, filed a provisional patent application, and applied for the trademark. We're looking to equity crowdfunding to further advance our intellectual property portfolio and initiate the licensing process that's key to our strategy to make the J-needle™ the industry standard.

Dr. Soloway is using the J-needle™ to treat a patient with trigger finger.

Picture showing a case of trigger finger.

What is the J-needle™?    

The J-needle™ uses our patent pending technology to optimize the delivery of medicine to points of interest under the skin that's otherwise difficult to access. The shape, length, and other characteristics of the needle are specifically designed to enhance the needling process. This not only saves time for the patient and doctor or medical professional that's administering the injection but also improves the accuracy of the medical procedure. 

In some cases, use of the J-needle™ will enable the doctor to avoid piercing sensitive tissue that may otherwise cause unnecessary pain or other medical complications.  There are several medical applications for the J-needle™, such as:

  • Rheumatology (treat joint pain)
  • Plastic Surgery (cosmetic and reconstructive surgery)
  • Neurology (treat brain and spinal cord diseases)
  • Anesthesiology (for pain management)
  • Ophthalmology (for eye injections)
  • Orthopedics (surgical and nonsurgical treatments for musculoskeletal trauma)
  • Podiatry (for foot injections)

How is the J-needle™ Different?

Simply put, our J-needle™ is different than other needles on the market because we've designed it for specific medical purposes and treatments. Currently, when a doctor selects a needle to inject medicine to treat trigger finger or other ailments, s/he can choose from an array of needles of different gauges and different lengths.  

However, there are no options for needles with different curvatures and shapes to avoid piercing sensitive tissue or encountering obstructions that are under the skin. The J-needle™ solves this problem by being specifically designed to streamline and improve treatments. 

In the case of trigger finger, the curvature, length, and gauge are optimized for the required treatment. Other ailments will similarly have needles that are designed specifically for the required treatment. 

Our strategy is to design, develop, and subsequently license the J-needle™ to current manufacturers where we would generate royalty revenue. We intend to leverage the intellectual property portfolio to create needles that are optimally designed for each ailment. 

The Health Care Market Is Enormous

We endeavor to be a key player in the health care industry. This is the largest industry in the United States with claim to annual revenue of $1.7 trillion  generated by almost 800,000 health care companies employing 17 million people (source: Statistic Brain). Our initial focus will be on the 5,600 rheumatologists and 5,000 rheumatology nurses working in the US (source: 2015 Workforce Study of Rheumatology Specialists in the United States) that treat trigger finger. Subsequently we will be targeting a much larger portion of the market that includes other applications for the J-needle™ such as plastic surgery, neurology, anesthesiology, ophthalmology, orthopedics, and podiatry.

Prevalence of Trigger Finger Correlates to Diabetes

Trigger finger is a musculoskeletal ailment that affects the tendons of fingers or thumbs. Although it is not a dangerous condition, it certainly affects quality of life. The patient may have difficulty flexing or extending the finger. It's often stuck in the bent position then straightens with a trigger-like snap. In severe cases, the finger is locked in the flexed position. 

The condition occurs more often in women than men and it occurs mostly in people between 40 and 60 years old. Patients with diseases such as diabetes, rheumatoid arthritis, and hypothyroidism are more likely to develop trigger finger. The condition affects 2 to 3% of the general population and 10 to 20% of those with diabetes (source for data in this paragraph: Diabetes Forecast).

Source: Diabetes 2030: Insights from Yesterday, Today, and Future Trends

The incidents and prevalence of trigger finger is directly correlated to that of diabetes. The more diabetics the more cases of trigger finger. In 2015 there was an estimated 30.3 million people (9.4% of the US population) with diabetes. This includes 1.5 million new cases, of which approximately half were in the age group that are most likely to develop trigger finger (source: National Diabetes Statistics Report, 2017). The graph above shows the forecast for the total US population and the number of diabetics. Note that the number of cases of diabetes is expected to grow by 54% (Source: Diabetes 2030: Insights from Yesterday, Today, and Future Trends).

In the Press

Vineland rheumatologist Dr. Soloway save Bridgeton redident with rare disease

Dr. Soloway diagnosed and treated 22 year old woman with a rare disease.

Dr. Stephen Soloway Named to "Top Doctors" List by U.S. News & World Report

Dr. Soloway was named one of the nation's top doctors by U.S. News & World Report in collaboration with Castle Connolly.

Offering Summary

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000:

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
Cash And Cash Equivalents
Accounts Receivable
Short Term Debt
Long Term Debt
Revenues And Sales
Costs Of Goods Sold
Taxes Paid
Net Income


A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Thank you to investors

over 4 years ago

We’re humbled by the support we’ve received from our investors and the StartEngine community. Within two short weeks since the launch of our campaign, we already achieved and surpassed the minimum target. We’re excited to have received investments from several physicians of multiple specialties and other healthcare professionals that see the value of the J-needleTM  and want to use it to improve patient care.

Although we’ve quickly surpassed the minimum target, we’re still a long way off from our maximum target of $100,000. Please share the link for our campaign ( on your social media to help get the word out to other potential investors.

Thank you for your support.

The Jasperate Team

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}